Clinical Trials Logo

Clinical Trial Summary

Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases


Clinical Trial Description

Protocol Number: IM-2021A Study Stage: Phase I Study Number: 2-3 sites Subject Number: up to 94 patients with recurrent or metastatic solid tumors, for whom there are no available effective standard treatments or for whom standard treatments have proven ineffective or intolerable. ;


Study Design


Related Conditions & MeSH terms

  • Recurrent or Metastatic Solid Tumors

NCT number NCT06093698
Study type Interventional
Source ITabMed Co., Ltd.
Contact Darong Dai, Bachelor
Phone 8618284820495
Email darong.dai@itabmed.com
Status Not yet recruiting
Phase Phase 1
Start date December 1, 2023
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT02221960 - A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors Phase 1
Recruiting NCT06330064 - A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors Phase 2